Clinical Trial Update: Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update studying the effect of the GCGR antisense drug ISIS GCGRRx on hepatic lipid and glycogen content in people with Type 2 diabetes. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• ISIS-GCGRRx

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED